Skip to main content
. 2021 Dec 13;5:PO.21.00135. doi: 10.1200/PO.21.00135

FIG 2.

FIG 2.

Co-occurring MET amplification and secondary mutations. (A) VAF of METex14 concurrent with MET amplification versus METex14 only in Guardant360. (B) Second site MET mutations in patients with METex14 non–small-cell lung cancer in Guardant360 and GenePlus data sets. IPT, immunoglobulin plexins transcription domains; METex14, MET exon 14 skipping alterations; PSI, plexins-semaphorin-integrin domain; TM, transmembrane domain; VAF, variant allele frequency.